PURPOSE: We surveyed American Urological Association members to determine factors that influence the treatment of patients with small renal masses. MATERIALS AND METHODS: In June 2009 American Urological Association members were solicited to complete an online survey. Respondents were asked their preferred treatment for 8 cases and 3 index patients. In each case computerized tomographic axial and schematic coronal images were provided. RESULTS: A total of 759 active urologists with varied training backgrounds and clinical practice settings completed the survey. Tumor size (OR 8.4, 95% CI 7.1-10.1), tumor depth (OR 19.2, 95% CI 14.8-25.0) and tumor location (OR 24.0, 95% CI 18.1-31.8) were markedly associated with preference for radical nephrectomy instead of partial nephrectomy. Fellowship trained urologists (OR 0.4, 95% CI 0.2-0.6) and urologists at academic hospitals (OR 0.6, 95% CI 0.4-0.9) were less likely to choose radical nephrectomy. Respondents were more likely to choose active surveillance in an older patient (OR 2.7, 95% CI 2.1-3.6) or in a patient with comorbidities (OR 10.0, 95% CI 8.0-12.4). Urologists were less likely to choose active surveillance for a 4 vs 2 cm tumor (OR 0.18, 95% CI 0.15-0.21). Active surveillance was chosen more often if the tumor was perihilar vs mid kidney (OR 2.0, 95% CI 1.8-2.3) or polar (OR 2.1, 95% CI 1.9-2.5). CONCLUSIONS: There is considerable heterogeneity in the treatment of patients with clinical T1a tumors. Several factors explain these differences as selected treatments are independently associated with tumor, patient and urologist factors. Copyright Â
PURPOSE: We surveyed American Urological Association members to determine factors that influence the treatment of patients with small renal masses. MATERIALS AND METHODS: In June 2009 American Urological Association members were solicited to complete an online survey. Respondents were asked their preferred treatment for 8 cases and 3 index patients. In each case computerized tomographic axial and schematic coronal images were provided. RESULTS: A total of 759 active urologists with varied training backgrounds and clinical practice settings completed the survey. Tumor size (OR 8.4, 95% CI 7.1-10.1), tumor depth (OR 19.2, 95% CI 14.8-25.0) and tumor location (OR 24.0, 95% CI 18.1-31.8) were markedly associated with preference for radical nephrectomy instead of partial nephrectomy. Fellowship trained urologists (OR 0.4, 95% CI 0.2-0.6) and urologists at academic hospitals (OR 0.6, 95% CI 0.4-0.9) were less likely to choose radical nephrectomy. Respondents were more likely to choose active surveillance in an older patient (OR 2.7, 95% CI 2.1-3.6) or in a patient with comorbidities (OR 10.0, 95% CI 8.0-12.4). Urologists were less likely to choose active surveillance for a 4 vs 2 cm tumor (OR 0.18, 95% CI 0.15-0.21). Active surveillance was chosen more often if the tumor was perihilar vs mid kidney (OR 2.0, 95% CI 1.8-2.3) or polar (OR 2.1, 95% CI 1.9-2.5). CONCLUSIONS: There is considerable heterogeneity in the treatment of patients with clinical T1a tumors. Several factors explain these differences as selected treatments are independently associated with tumor, patient and urologist factors. Copyright Â
Authors: Joseph B Song; Jeremiah J Morrissey; Jonathan M Mobley; Karen G Figenshau; Joel M Vetter; Sam B Bhayani; Evan D Kharasch; Robert Sherburne Figenshau Journal: Int J Urol Date: 2018-11-22 Impact factor: 3.369
Authors: Bruce L Jacobs; Hung-Jui Tan; Jeffrey S Montgomery; Alon Z Weizer; David P Wood; David C Miller; J Stuart Wolf; Khaled S Hafez Journal: Urology Date: 2012-05 Impact factor: 2.649
Authors: Kenan E Celtik; Paras H Shah; Vinay R Patel; Daniel M Moreira; Arvin K George; Valerio Iacovelli; Manaf Alom; Andrew Ng; Amin Herati; Simpa S Salami; Hannah Bierwiler; Michael J Schwartz; Lee Richstone; Joph Steckel; Manish A Vira; Louis R Kavoussi Journal: World J Urol Date: 2016-11-01 Impact factor: 4.226
Authors: Hung-Jui Tan; Anne-Marie Meyer; Tzy-Mey Kuo; Angela B Smith; Stephanie B Wheeler; William R Carpenter; Matthew E Nielsen Journal: Cancer Date: 2014-11-19 Impact factor: 6.860
Authors: Luke T Lavallée; Simon Tanguay; Michael A Jewett; Lori Wood; Anil Kapoor; Ricardo A Rendon; Ronald B Moore; Louis Lacombe; Jun Kawakami; Stephen E Pautler; Darrel E Drachenberg; Peter C Black; Jean-Baptiste Lattouf; Christopher Morash; Ilias Cagiannos; Zhihui Liu; Rodney H Breau Journal: Can Urol Assoc J Date: 2015 Mar-Apr Impact factor: 1.862
Authors: Brett A Johnson; Sandy Kim; Ryan L Steinberg; Alberto Diaz de Leon; Ivan Pedrosa; Jeffrey A Cadeddu Journal: Urol Oncol Date: 2019-09-17 Impact factor: 3.498
Authors: Jeffrey J Tomaszewski; Robert G Uzzo; Neil Kocher; Tianyu Li; Brandon Manley; Reza Mehrazin; Timothy Ito; Philip Abbosh; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Daniel Canter; Marc C Smaldone; Alexander Kutikov Journal: Urol Oncol Date: 2014-06-07 Impact factor: 3.498